﻿<?xml version="1.0" encoding="UTF-8"?>
<ArticleSet>
  <Article>
    <Journal>
      <PublisherName>Tabriz University of Medical Sciences</PublisherName>
      <JournalTitle>Pharmaceutical Sciences</JournalTitle>
      <Issn>1735-403X</Issn>
      <Volume>32</Volume>
      <Issue>1</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month>01</Month>
        <DAY>07</DAY>
      </PubDate>
    </Journal>
    <ArticleTitle>The Modulatory Effect of Liraglutide on the Expression of GPX4, HO-1 and SLC7A11 Signaling Pathway in Obese Rats</ArticleTitle>
    <FirstPage>102</FirstPage>
    <LastPage>109</LastPage>
    <ELocationID EIdType="doi">10.34172/PS.026.43381</ELocationID>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName>Mahmood Jameel</FirstName>
        <LastName>Saeed</LastName>
        <Identifier Source="ORCID">https://orcid.org/0009-0003-4000-5797</Identifier>
      </Author>
      <Author>
        <FirstName>Inam Sameh</FirstName>
        <LastName>Arif</LastName>
        <Identifier Source="ORCID">https://orcid.org/0000-0002-9194-1919</Identifier>
      </Author>
    </AuthorList>
    <PublicationType>Journal Article</PublicationType>
    <ArticleIdList>
      <ArticleId IdType="doi">10.34172/PS.026.43381</ArticleId>
    </ArticleIdList>
    <History>
      <PubDate PubStatus="received">
        <Year>2025</Year>
        <Month>09</Month>
        <Day>30</Day>
      </PubDate>
      <PubDate PubStatus="accepted">
        <Year>2025</Year>
        <Month>11</Month>
        <Day>22</Day>
      </PubDate>
    </History>
    <Abstract>Background: Obesity, a multifaceted metabolic condition, is associated with oxidative stress and disrupted redox homeostasis, leading to ferroptosis and metabolic dysfunction. Liraglutide, a well-known glucagon-like peptide-1 (GLP-1) receptor agonist, is used in the treatment of obesity. This study aimed to examine the modulatory effects of liraglutide on oxidative stress and ferroptosis-related indicators in obese rats induced by high-fat diet (HFD). Methods: Thirty-five male Wistar rats were randomly divided into five groups: a control group, an HFD-induced obesity group, and three liraglutide treatment groups (100, 200, and 400 μg/kg/day). Following a 4-week induction of HFD, liraglutide was administered subcutaneously for 28 days. Redox and ferroptosis changes were assessed by measuring serum iron, TfR-1, malondialdehyde (MDA), and superoxide dismutase (SOD), along with gene expression of SLC7A11 and the immunohistochemical expression of heme oxygenase-1 (HO-1) and glutathione peroxidase 4 (GPX4) in hepatic tissues. Results: HFD-induced obesity significantly reduced the expression of antioxidant and ferroptosis-regulatory markers. Liraglutide treatment, particularly at high doses, significantly reversed these effects by upregulating SLC7A11 gene expression and enhancing HO-1, and GPX4 protein expression in a dose-dependent manner. Conclusion: These findings suggest that liraglutide restores antioxidant capacity and inhibits ferroptosis through activation of the SLC7A11/HO-1/GPX4 axis. Beyond its metabolic benefits, liraglutide exerted cytoprotective effects, highlighting its potential therapeutic role in obesity-associated oxidative stress and ferroptosis injury.  </Abstract>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Obesity</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Ferroptosis</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Liraglutide</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">GPX4</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">HO-1</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">SLC7A11</Param>
      </Object>
    </ObjectList>
  </Article>
</ArticleSet>